Monte Carlo probabilistic sensitivity analysis for patient level simulation models: Efficient estimation of mean and variance using ANOVA

被引:81
作者
O'Hagan, Anthony [1 ]
Stevenson, Matt
Madan, Jason
机构
[1] Univ Sheffield, Dept Probabil & Stat, Sheffield S3 7RH, S Yorkshire, England
[2] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England
关键词
analysis of variance; cost-effectiveness; economic evaluation; economic model; individual-level simulation; micro-simulation; Monte Carlo; patient-level model; probabilistic sensitivity analysis;
D O I
10.1002/hec.1199
中图分类号
F [经济];
学科分类号
02 ;
摘要
Probabilistic sensitivity analysis (PSA) is required to account for uncertainty in cost-effectiveness calculations arising from health economic models. The simplest way to perform PSA in practice is by Monte Carlo methods, which involves running the model many times using randomly sampled values of the model inputs. However, this can be impractical when the economic model takes appreciable amounts of time to run. This situation arises, in particular, for patient-level simulation models (also known as micro-simulation or individual-level simulation models), where a single run of the model simulates the health care of many thousands of individual patients. The large number of patients required in each run to achieve accurate estimation of cost-effectiveness means that only a relatively small number of runs is possible. For this reason, it is often said that PSA is not practical for patient-level models. We develop a way to reduce the computational burden of Monte Carlo PSA for patient-level models, based on the algebra of analysis of variance. Methods are presented to estimate the mean and variance of the model output, with formulae for determining optimal sample sizes. The methods are simple to apply and will typically reduce the computational demand very substantially. Copyright (C) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:1009 / 1023
页数:15
相关论文
共 26 条
[1]  
Barton P, 2004, HEALTH TECHNOL ASSES, V8, P1
[2]  
Barton Pelham, 2004, J Health Serv Res Policy, V9, P110, DOI 10.1258/135581904322987535
[3]  
Box GEP., 1987, EMPIRICAL MODEL BUIL
[4]   Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK [J].
Brennan, A ;
Bansback, N ;
Reynolds, A ;
Conway, P .
RHEUMATOLOGY, 2004, 43 (01) :62-72
[5]   A taxonomy of model structures for economic evaluation of health technologies [J].
Brennan, Alan ;
Chick, Stephen E. ;
Davies, Ruth .
HEALTH ECONOMICS, 2006, 15 (12) :1295-1310
[6]   Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease [J].
Briggs, AH ;
Goeree, R ;
Blackhouse, G ;
O'Brien, BJ .
MEDICAL DECISION MAKING, 2002, 22 (04) :290-308
[7]   Clinical impact and health economic consequences of posttransplant type 2 diabetes mellitus [J].
Chilcott, JB ;
Whitby, SM ;
Moore, R .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (5A) :32S-39S
[8]   The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies [J].
Claxton, K .
JOURNAL OF HEALTH ECONOMICS, 1999, 18 (03) :341-364
[9]   Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra [J].
Claxton, K ;
Sculpher, M ;
McCabe, C ;
Briggs, A ;
Akehurst, R ;
Buxton, M ;
Brazier, J ;
O'Hagan, T .
HEALTH ECONOMICS, 2005, 14 (04) :339-347
[10]  
Cronin KA, 1998, STAT MED, V17, P2509, DOI 10.1002/(SICI)1097-0258(19981115)17:21<2509::AID-SIM949>3.3.CO